Ludwig Gerd, Mojić Marija, Bulatović Mirna, Mijatović Sanja, Maksimović-Ivanić Danijela, Steinborn Dirk, Kaluđerović Goran N
Department of Bioorganic Chemistry, Leibniz-Institute of Plant Biochemistry, Weinberg 3, D 06120 Halle (Saale) Germany.
Anticancer Agents Med Chem. 2016;16(11):1455-1460. doi: 10.2174/1871520615666151029100749.
In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.
使用钌（II）和类似的铱（III）配合物[Ru(η6 - 对异丙基苯)Cl2{Ph2PCH2CH2CH2S(O)xPh - κP}]、[Ru(η6 - 对异丙基苯)Cl{Ph2PCH2CH2CH2S(O)xPh - κP,κS}][PF6]（1 - 4）、[Ir(η5 - C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh - κP}]和[Ir(η5 - C5Me5)Cl{Ph2PCH2CH2CH2S(O)xPh - κP,κS}][PF6]（5 - 8；x = 0, 1）进行的体外研究表明，这些配合物对8505C、A253、MCF - 7、SW480和518A2癌细胞系具有高选择性。因此，阳离子钌配合物4被证明是最具选择性的。对于中性和阳离子钌配合物1 - 4，半胱天冬酶依赖性凋亡性细胞死亡被证明是该药物对8505C细胞系产生杀肿瘤作用的主要原因。
